Logo

Nykode Therapeutics Reports Final P-II Trial (VB-C-02) Results of VB10.16 + Tecentriq (atezolizumab) for Advanced Cervical Cancer

Share this

Nykode Therapeutics Reports Final P-II Trial (VB-C-02) Results of VB10.16 + Tecentriq (atezolizumab) for Advanced Cervical Cancer

Shots:

  • The P-II trial evaluating VB10.16 + Roche’s Tecentriq in 52 patients with advanced or recurrent, non-resectable HPV16+ cervical cancer at sites in the EU
  • The results showed an m-OS of ≥25mos. (not reached) & m-PFS of 6.3mos. in PD-L1+ patients while m-OS for the overall population incl. patients with PD-L1- tumors (16.9mos.), m-PFS (4.1mos.), DoR (17.1mos), ORR & DCR (29% & 75%) in PD-L1+ patients (19% & 60% in the overall population)
  • In PD-L1+ patients with one prior line of systemic treatment, ORR & DCR (40% & 80%) with a m-PFS (16.9mos.) & m-OS of ≥25mos. (not reached), was well-tolerated and the safety profile was comparable to checkpoint inhibitor monotx. The company plans to initiate a registrational trial for PD-L1+ patients in the US in Q4’23

Ref: GlobeNewswire | Image: Nykode

Related News:-  Nykode Reports Interim Results of VB10.16 in P-II (VB C-02) Trial for the Treatment of Advanced Cervical Cancer

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions